that prostate cancer tumors contain a frequent deletion of the WAVE 1
gene. What’s important, though, is that this WAVE1 gene deletion occurs
in metastatic and lethal cancer, thus suggesting that, the WAVE1 gene
loss may represent an aggressive subtype of prostate cancer which is
more challenging to treat and more likely to progress.”
also raises the possibility that these GLDC-dependent cells could be
killed with drugs that block GLDC activity, according to the
researchers, who are now seeking potential drug compounds that could do
history, oral contraceptive use, and hormone therapy replacement was
evaluated in the 160,855 women eligible to be included in the analysis.
Incident lung cancer was observed in 2,467 and the median follow-up was
The ability to
accurately predict the risk of breast cancer could have a powerful
impact on medicine. It could clearly show which women need drugs, such
as tamoxifen and raloxifene, to reduce the risk of breast cancer. The
lowest-risk women may not need breast cancer screening, while those at
highest risk might need to start earlier.
Our study is
the most definitive so far to show the clear benefits of using genetic
testing for a large number of genetic risk factors in identifying women
at elevated risk of developing breast cancer.
researchers used computational analysis to predict unique neoantigens
from the tumour genomic information and select those likely to be the
best targets for vaccine. The approach was said to be ‘more like a
sniper than a bomb’ – using the neoantigens as flags to specifically
target the cancer cells.
Even the Duke
treatment that got such high-profile 60 Minutes treatment is not a sure
bet for success: Half the patients in the initial trial did not survive,
a fact that was glossed over during the report. Thompson believes that
understanding the patients who don’t respond to virus-based treatments
will be as important as celebrating those who do.
KEYTRUDA are members of a class of cancer treatments known as
immuno-oncology therapies. Data from preclinical studies suggest that
Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may
lead to an enhanced anti-tumor immune response. The results from
KEYNOTE-046 will determine the future clinical development program for
engagement with the community of researchers and institutions, ORCID
will develop localized technical support infrastructure and materials to
support the implementation of persistent identifiers in research